Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Recruiting now · Not applicable

Conditions studied: Bronchopulmonary Dysplasia, Pulmonary Hypertension

In brief

Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.

Key facts

Study ID

NCT06373289

Run by

University of Alabama at Birmingham

People needed

39

Starts

2026-07-15

Expected to finish

2029-12-01

Last updated by the study team

2026-06-17

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Between 22w 0/7d and 31w 6/7d gestation at birth
• Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
• Receiving supplemental oxygen
• Have mature retinas

You may not qualify if…

• Major congenital anomalies

Where it is running

• The University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
• Yale New Haven Hospital — New Haven, Connecticut, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.